Retirement Systems of Alabama Has $2.39 Million Stock Position in Catalent, Inc. (NYSE:CTLT)

Retirement Systems of Alabama reduced its position in shares of Catalent, Inc. (NYSE:CTLT) by 1.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,375 shares of the company’s stock after selling 548 shares during the period. Retirement Systems of Alabama’s holdings in Catalent were worth $2,385,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Oddo BHF Asset Management Sas bought a new stake in Catalent during the third quarter valued at about $8,480,000. Tidal Investments LLC bought a new stake in Catalent during the 3rd quarter valued at approximately $214,000. Neo Ivy Capital Management acquired a new stake in Catalent in the 3rd quarter valued at approximately $1,078,000. Nomura Asset Management Co. Ltd. increased its position in Catalent by 1.4% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock worth $3,211,000 after buying an additional 750 shares during the period. Finally, National Bank of Canada FI increased its position in Catalent by 300.0% in the 3rd quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock worth $88,481,000 after buying an additional 1,095,578 shares during the period.

Catalent Price Performance

NYSE:CTLT opened at $63.48 on Friday. The company has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15. The company has a 50-day moving average of $60.58 and a 200-day moving average of $59.30. Catalent, Inc. has a 52 week low of $41.15 and a 52 week high of $63.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, equities research analysts anticipate that Catalent, Inc. will post 0.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CTLT shares. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday, December 10th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. Based on data from MarketBeat, Catalent currently has an average rating of “Hold” and a consensus price target of $63.40.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.